Photo of Anna Migliaccio

Anna Migliaccio

  • PROFESSOR Medicine, Hematology and Medical Oncology
Print ProfilePrint Profile

Education

  • Radiobiological Institute, TNO (Rijswiik, The Netherlands)

  • University of Washington (Seattle, WA)
    Hematology

  • Ph.D., University of Naples (Naples, Italy)
    Natural Science

  • Ph.D., University of Naples (Naples, Italy)
    Biological Science

Awards

  • 2008 - 2013
    Editorial Board
    Blood

  • 2007 - Present
    Editorial Board
    Leukemia

  • 2005 - Present
    Editorial Board
    Stem Cells

  • 1994 - 1999
    Editorial Board
    Blood

  • 1992 - 1995
    Editorial Board
    International Journal Hematology

  • 1992 - 1995
    Editorial Board
    Experimental Hematology

Research

2006-2010
P01-CA108671-04
"Mouse models of Myelofibrosis"
The scope of this project is to exploit the Gata1low mouse model to detail the pathobiological pathway  leading to development of increased stem/progenitor cell trafficking and extramedullary hematopoiesis in myleofibrosis

2007-2010
New York State Star Program:
 "Personalized Therapies for Sickle Cell Disease and Thalassemia."
The scope of this project is to develop in vitro assays to predict the response to therapy with histone deacetylase inhibitors of sickle cell and thalassemia patients.  2004-2009
Member of the Program for Excellency in Training  "Eurythron"  European Community
The scope of this project is to establish a multicenter excellence training program in Experimental Hematology
 

Publications

Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio M, Orkin SH, Migliaccio AR. The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 2007; 109: 1460-1471.

Martelli F, Ghinassi B, Panetta B, Alfani E, Gatta V, Pancrazzi A, Bogani C, Vannucchi AM, Paoletti F, Migliaccio G, Migliaccio AR. Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic background. Blood 2005; 106: 4102-4113.

Vannucchi AM, Bianchi L, Paoletti F, Pancrazi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR. A patho-biological pathway linking thrombopoietin, GATA-1 and TGF-B1 in the development of myelofibrosis. Blood 2005; 105: 3493-3501.

Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, Langella V, Di Virgilio A, Vannucchi AM, Migliaccio AR. Increased and pathological emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood 2004; 104: 3573-3579.

Migliaccio AR, Rana RA, Sanchez M, Lorenzini R, Migliaccio G, Orkin SH. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-low mouse mutant. J Exp Med 2003; 197: 281-296.

Vannucchi A, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (Gata-1low mice). Blood 2002; 100: 1123-1132.

Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell dose. Blood 2000; 96: 2717-2722.

Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrilla L, Taylor P, Stevens C. Initial results of the placental/umbilical cord blood program for unrelated bone marrow reconstitution. New Engl J Med 1998; 339: 1565-1577.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Migliaccio did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Annenberg Building Floor 24 Room 64-A
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-6974
Fax: 212-876-5276

Address

Basic Sciences Building Floor 24 Room 60
10 East 101st Street
New York, NY 10029


Address

One Gustave L Levy Place
Box 1079
New York, NY 10029